Tfrc Antibody

What is TFRC and why is it a significant target for antibody development?

TFRC (Transferrin Receptor C, also known as CD71) is a critical cell surface protein involved in cellular iron uptake, essential for various cellular processes and maintenance of iron homeostasis. It represents a significant research target due to its increased expression in malignant tissues compared to normal counterparts, as cancer cells require larger amounts of iron to maintain their high proliferation rates. This differential expression makes TFRC an attractive target for immunotherapy and delivery of cytotoxic agents . The receptor's role in iron metabolism creates a unique opportunity for researchers to target cellular growth through iron deprivation mechanisms using TFRC-specific antibodies.

What are the primary types of TFRC antibodies available for research?

Research-grade TFRC antibodies are available in several formats, including monoclonal rabbit antibodies that offer high specificity and reproducibility. Based on the search results, there are recombinant monoclonal antibodies like the ones produced by inserting the TFRC antibody-encoding gene into expression vectors , as well as complete human anti-human TFRC antibodies developed through phage-display technology . Additionally, researchers can access polyclonal antibodies that provide broader epitope recognition. These antibodies are available in different forms including liquid preparations containing Rabbit IgG in phosphate buffered saline (with 150mM NaCl, 0.02% sodium azide and 50% glycerol) and lyophilized preparations that require reconstitution prior to use .

What experimental applications are supported by commercially available TFRC antibodies?

TFRC antibodies support multiple experimental applications critical for both basic and translational research:

These applications provide researchers with a comprehensive toolkit for investigating TFRC expression, localization, and functional characteristics across multiple experimental systems.

How should researchers design experiments to evaluate TFRC expression in different cell or tissue types?

When evaluating TFRC expression across different biological samples, researchers should implement a multi-modal approach. Begin with RT-qPCR using validated primers (e.g., TFRC forward: 5′-CATCAGCCTCCTGGTTATGG-3′, reverse: 5′-AAATGCCTCCGCTTATGTTG-3′) to quantify transcript levels. Follow with protein-level validation using Western blot analysis, loading approximately 30 μg of protein lysate per lane and utilizing an antibody concentration of 0.5 μg/mL for optimal signal-to-noise ratio . For cellular localization, employ immunofluorescence or flow cytometry, incubating cells with anti-TFRC antibody on ice for 1 hour followed by appropriate fluorophore-conjugated secondary antibodies . For tissue distribution studies, perform IHC on paraffin-embedded sections with heat-mediated antigen retrieval in citrate buffer (pH6) for 20 minutes, blocking with 10% goat serum, and incubating with 1μg/ml anti-TFRC antibody . This comprehensive approach ensures reliable cross-validation of expression patterns across different analytical platforms.

What are the optimal storage and handling conditions for maintaining TFRC antibody activity?

To maintain optimal TFRC antibody activity, rigorous storage and handling protocols must be followed. For long-term storage, maintain antibodies at -20°C for up to one year from receipt date . For monoclonal antibodies in liquid form, avoid repeated freeze-thaw cycles that can lead to antibody degradation and reduced affinity . For frequent use within one month, store at 4°C to minimize freeze-thaw damage while maintaining activity . Lyophilized antibody preparations offer extended shelf life and should be reconstituted with deionized water or equivalent to achieve the manufacturer's recommended concentration (typically yielding 1.0 mL final volume) . After reconstitution, lyophilized preparations may be stored at 4°C for one month or aliquoted and frozen at -20°C for up to six months . Creating single-use aliquots minimizes freeze-thaw cycles and maintains antibody integrity for sensitive applications like flow cytometry and immunoprecipitation.

How can researchers validate the specificity of TFRC antibodies in their experimental systems?

Rigorous validation of TFRC antibody specificity requires multiple complementary approaches. First, perform Western blot analysis across multiple cell lines known to express varying levels of TFRC (e.g., Hela, K562, HT1080 for human samples; RAW264.7 and SP2/0 for rodent samples) to confirm detection of the expected ~95 kDa band (noting the calculated molecular weight is approximately 85 kDa) . Second, implement a gene knockdown validation using TFRC-specific shRNA constructs in your experimental system; the effectiveness of knockdown can be verified using a vector such as pSIREN-retroQ-ZsGreen plasmid containing cloned sequences targeting human TFRC . Third, conduct blocking experiments by pre-incubating the antibody with its specific immunogen peptide prior to application in your detection system; this should substantially reduce or eliminate specific signal. Finally, include both positive control tissues known to express TFRC (e.g., placenta) and negative controls (primary antibody omission, isotype controls) in all experiments to distinguish specific from non-specific binding.

How can TFRC antibodies be utilized to investigate cancer cell metabolism and proliferation?

TFRC antibodies offer powerful tools for investigating the critical relationship between iron metabolism and cancer cell proliferation. Researchers can employ anti-TFRC antibodies in functional blocking studies to disrupt the interaction between transferrin and its receptor, thereby inhibiting iron uptake and inducing iron deprivation-mediated growth suppression . This approach allows for mechanistic studies of cellular responses to iron restriction. Experimentally, researchers should conduct cell proliferation assays (e.g., MTT assays) with OSCC or other cancer cells (2 × 10^4 cells/mL) incubated with various concentrations of anti-TFRC antibody at 37°C and 5% CO2 . Complementary assessments should include apoptosis induction analysis, as TFRC antibody-mediated iron deprivation has been demonstrated to induce programmed cell death in malignant cells . For comprehensive metabolic analysis, researchers should combine these functional assays with measurements of intracellular iron levels, mitochondrial function, and expression of iron-dependent enzymes to fully characterize the metabolic consequences of TFRC inhibition in cancer cells.

What strategies can be employed to develop TFRC antibodies with enhanced therapeutic potential?

Development of TFRC antibodies with enhanced therapeutic potential requires sophisticated antibody engineering approaches. Building upon the foundation of human anti-human TFRC antibodies previously established through phage-display technology , researchers should first optimize antibody binding characteristics through affinity maturation, employing directed evolution or rational design strategies to enhance target specificity and binding strength. The therapeutic efficacy can be further improved by engineering antibodies with modified Fc regions to enhance antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) activity, which can be quantitatively assessed using lactate dehydrogenase (LDH)-releasing assays . Additionally, researchers should explore the development of antibody-drug conjugates (ADCs) by coupling cytotoxic payloads to TFRC antibodies, exploiting the receptor's internalization properties for targeted drug delivery to cancer cells. Finally, bispecific antibody formats that simultaneously engage TFRC and immune effector cells represent a promising approach to enhance anti-tumor immunity while targeting the altered iron metabolism of cancer cells.

How can TFRC antibodies be applied in xenograft models to evaluate anti-cancer efficacy?

Implementation of TFRC antibodies in xenograft models requires careful experimental design to evaluate therapeutic potential. Based on published approaches , researchers should establish xenograft models using human cancer cell lines (such as OSCC cells) in immunocompromised mice. Once tumors reach approximately 100 mm³, systematically administer complete human anti-human TFRC antibody at defined doses (typically ranging from 5-20 mg/kg) via intraperitoneal or intravenous routes, with treatment schedules optimized for the specific model (typically 2-3 times per week for 2-4 weeks). Tumor measurements should be conducted using digital calipers every 2-3 days, calculating tumor volume using the formula: (length × width²)/2. Beyond tumor growth inhibition assessment, researchers should collect tissues for comprehensive analysis including: 1) immunohistochemical evaluation of TFRC expression in tumors, 2) TUNEL assays to quantify apoptosis induction, 3) Ki-67 staining to assess proliferation rates, and 4) measurement of intratumoral iron levels to confirm the mechanism of action. Additionally, monitoring of potential toxicities through body weight measurements, complete blood counts, and histopathological examination of major organs is essential for evaluating the safety profile of TFRC antibody-based therapies.

What are common issues in Western blot applications of TFRC antibodies and how can they be resolved?

Western blot analysis with TFRC antibodies can present several technical challenges that require systematic troubleshooting:

For optimal results, electrophoresis should be performed on 5-20% SDS-PAGE gels at 70V (stacking)/90V (resolving) for 2-3 hours, followed by protein transfer to nitrocellulose membranes at 150 mA for 50-90 minutes .

How can researchers address variability in immunohistochemical staining with TFRC antibodies?

Variability in immunohistochemical staining with TFRC antibodies can significantly impact interpretation of experimental results. To address this challenge, researchers should first optimize antigen retrieval conditions through systematic comparison of heat-mediated retrieval in citrate buffer (pH 6.0) versus EDTA buffer (pH 9.0) , as TFRC epitope accessibility may vary across tissue types and fixation methods. Standardize tissue processing protocols, including consistent fixation times (preferably 24 hours in 10% neutral buffered formalin) and section thickness (4-5 μm). Implement rigorous blocking protocols using 10% goat serum to minimize non-specific binding , with blocking duration extended to 1 hour for tissues with high background. Titrate primary antibody concentrations systematically (0.5-2 μg/ml) to determine optimal signal-to-noise ratio for each tissue type, and standardize incubation conditions (overnight at 4°C recommended for consistent results). Include appropriate positive controls (placenta tissue) and negative controls (primary antibody omission, isotype control) in each staining batch. Finally, implement quantitative image analysis using digital pathology tools to objectively measure staining intensity and distribution, reducing subjective interpretation variability.

What precautions should be taken when using TFRC antibodies in flow cytometry applications?

When employing TFRC antibodies for flow cytometry applications, several critical precautions must be implemented to ensure reliable and reproducible results:

• Sample preparation: Maintain cell viability above 95% through gentle handling and appropriate buffer usage; perform all procedures on ice to prevent receptor internalization and include sodium azide (0.02%) in staining buffers to inhibit metabolic processes .

• Antibody titration: Always perform antibody titration experiments to determine optimal concentration, typically starting with 1 μg per 10^6 cells and testing 2-fold dilutions to identify the concentration yielding maximum specific signal with minimal background.

• Control implementation: Include proper controls for each experiment: unstained cells, isotype controls matched to the primary antibody host species and subclass, and positive controls (cell lines with known TFRC expression like K562) .

• Blocking: Pre-incubate cells with FcR blocking reagent (5-10% normal serum from the same species as the secondary antibody) for 15-30 minutes before antibody staining to reduce non-specific binding .

• Washing efficiency: Perform at least three washing steps after antibody incubation using cold PBS containing 2% FBS to remove unbound antibody completely .

• Secondary antibody selection: When using indirect detection, select phycoerythrin-labeled secondary antibodies for optimal signal-to-noise ratio, ensuring minimal spectral overlap with other fluorophores in multi-parameter analysis .

• Instrument calibration: Calibrate the flow cytometer before each experimental session using appropriate calibration beads to ensure consistent fluorescence detection across experiments.

How might TFRC antibodies be utilized in developing targeted drug delivery systems?

TFRC antibodies present exceptional opportunities for developing targeted drug delivery systems due to the receptor's internalization properties and differential expression in rapidly proliferating cells. Researchers can exploit these characteristics by developing antibody-drug conjugates (ADCs) that combine the targeting specificity of anti-TFRC antibodies with potent cytotoxic payloads. The synthesis approach should involve conjugation of purified anti-TFRC antibodies with small molecule drugs through cleavable linkers (e.g., disulfide, hydrazone, or peptide linkers) that enable drug release in endosomal or lysosomal compartments following receptor-mediated endocytosis. Researchers should evaluate conjugation efficiency using mass spectrometry to confirm drug-to-antibody ratios, followed by functional assays to verify retained binding capacity to TFRC. In vitro efficacy testing should assess internalization kinetics using fluorescently-labeled antibodies and confocal microscopy, while cytotoxicity evaluations should compare ADC potency against unconjugated antibody and free drug controls in cell lines with varying TFRC expression levels. For in vivo evaluation, biodistribution studies using radiolabeled or fluorescently-tagged antibodies should precede efficacy studies in relevant animal models, with special attention to pharmacokinetic profiles and potential off-target toxicities.

What role might TFRC antibodies play in understanding and targeting cancer stem cells?

TFRC antibodies offer valuable tools for investigating the unique metabolic dependencies of cancer stem cells (CSCs), a subpopulation critical in tumor initiation, progression, and therapeutic resistance. Evidence suggests that CSCs may exhibit altered iron metabolism to support their self-renewal and differentiation capabilities. Researchers can utilize TFRC antibodies to identify and isolate CSC populations based on differential TFRC expression patterns, employing flow cytometry with anti-TFRC antibodies in combination with established CSC markers (e.g., CD44, CD133, ALDH). Following isolation, functional characterization should include sphere formation assays, limiting dilution transplantation experiments, and lineage tracing to confirm stemness properties. The metabolic dependencies of CSCs can be probed using anti-TFRC blocking antibodies to disrupt iron acquisition, followed by comprehensive metabolomic analysis to identify metabolic vulnerabilities unique to the CSC population. Furthermore, researchers should evaluate whether TFRC-targeted therapies can selectively eliminate CSCs by conducting in vivo limiting dilution assays following treatment with anti-TFRC antibodies, comparing tumor-initiating frequency between treated and control groups. This approach may reveal whether TFRC-targeted strategies can address the therapeutic resistance often associated with CSC populations, potentially leading to more effective cancer treatment regimens.

How can computational approaches enhance the design and application of TFRC antibodies?

Advanced computational approaches can dramatically enhance the design and application of TFRC antibodies across the research spectrum. Researchers should implement molecular dynamics simulations to model antibody-antigen interactions at the atomic level, identifying critical binding residues and optimizing binding affinity through in silico mutagenesis. Homology modeling can be employed to predict three-dimensional structures of novel anti-TFRC antibodies based on existing crystal structures, while computational docking algorithms can screen virtual antibody libraries to identify candidates with optimal binding characteristics. Machine learning approaches trained on existing antibody-antigen complexes can predict binding affinities and off-target interactions, accelerating the selection of lead candidates for experimental validation. For therapeutic applications, immunogenicity prediction algorithms should be utilized to identify and modify potential T-cell epitopes that might elicit unwanted immune responses. Systems biology approaches integrating transcriptomic, proteomic, and metabolomic data can help identify optimal contexts for TFRC antibody application by revealing cellular states with enhanced vulnerability to iron deprivation. Finally, pharmacokinetic/pharmacodynamic (PK/PD) modeling can optimize dosing regimens for in vivo studies, predicting antibody distribution, clearance, and target engagement to maximize therapeutic efficacy while minimizing potential toxicities.

What are the current limitations in TFRC antibody research and potential strategies to overcome them?

Current TFRC antibody research faces several significant limitations. First, the dual role of TFRC in normal physiology and pathological conditions presents a therapeutic window challenge, as complete inhibition may affect normal rapidly proliferating cells. This limitation might be addressed through the development of bispecific antibodies that recognize tumor-specific modifications of TFRC or through precise antibody engineering to target unique epitopes preferentially exposed in malignant contexts. Second, heterogeneous TFRC expression within tumors may lead to treatment resistance through selection of TFRC-low subpopulations. Researchers should investigate combination therapies targeting alternative iron acquisition pathways simultaneously, potentially preventing adaptive resistance. Third, the blood-brain barrier (BBB) presents a substantial obstacle for TFRC antibody delivery to brain malignancies, despite TFRC's expression on BBB endothelial cells. This challenge may be addressed through development of brain-penetrant antibody formats, including reduced-size antibody fragments or antibodies specifically designed to exploit TFRC-mediated transcytosis across the BBB. Finally, current preclinical models may insufficiently recapitulate the complex tumor microenvironment and systemic iron homeostasis. Implementation of patient-derived xenografts, humanized mouse models with intact immune systems, and ex vivo tumor slice cultures may provide more predictive platforms for evaluating TFRC antibody efficacy and mechanism of action.